 This is a parallel group, active control, single-center, open-label, randomized controlled trial comparing the safety and efficacy of initial therapy with an angiotensin converting enzyme ACE inhibitor lisinopril vs. beta-blocker therapy atenolol each administered three times weekly after dialysis. 